Last reviewed · How we verify

pramocaine

unknown active ✓ Verified Jun 2026

pramocaine is a drug. It is currently in unknown development for Allergic otitis externa, Arthropod bite wound, Burn injury.

Pramocaine is a small molecule with a modality of a topical anesthetic and antipruritic. It has been studied for various conditions including pruritis, focal seizure, muscle soreness, ichthyosis, and pruritus, and has been used as a treatment for uremic itch in adult hemodialysis patients.

At a glance

Generic namepramocaine
TargetSigma non-opioid intracellular receptor 1, Sodium channel alpha subunits; brain (Types I, II, III), Membrane-associated progesterone receptor component 1
Therapeutic areaInfectious Disease
Phaseunknown

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about pramocaine

What is pramocaine?

pramocaine is a pharmaceutical drug, indicated for Allergic otitis externa, Arthropod bite wound, Burn injury.

What is pramocaine used for?

pramocaine is indicated for Allergic otitis externa, Arthropod bite wound, Burn injury, Dry skin, Eruption of skin.

What development phase is pramocaine in?

pramocaine is in unknown.

What does pramocaine target?

pramocaine targets Sigma non-opioid intracellular receptor 1, Sodium channel alpha subunits; brain (Types I, II, III), Membrane-associated progesterone receptor component 1.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing